26 April 2018 - So far, few patients have received the new drugs, as commercial health plans and Medicare wrestle with how to cover the treatment.
The emergence of genetics-based medicines is pushing the cost of treating certain diseases to new levels, forcing hospitals and health insurers to reckon with how to cover total costs per patient approaching a million dollars.